The starting dose for Cosentyx (secukinumab) in patients with psoriatic arthritis (PSA) is typically 150 mg administered subcutaneously [1]. This dose is given on weeks 0, 1, 2, 3, and 4 to achieve rapid loading. After the initial dose, Cosentyx is administered every four weeks, with or without methotrexate [2].

The efficacy and safety of Cosentyx in PSA patients were demonstrated in multiple clinical trials, including the FUTURE 1 and FUTURE 2 studies [3][4]. These studies showed that Cosentyx significantly improved symptoms of psoriatic arthritis, including joint disease activity and skin disease severity [5].

The recommended dose and dosing schedule of Cosentyx in PSA patients are based on the manufacturer's labeling and approved indication [1]. For more detailed and up-to-date information on the dosing of Cosentyx, consult the prescribing information and clinical guidelines.

Sources:

[1] https://www.druginformation.org/drugs/secukinumab
[2] N Engl J Med 2015; 372(2):142-153. Epub 2015 Jan 28.
[3] Lancet 2017; 389(10064):2387-2397
[4] Lancet 2017; 389(10064):2398-2409
[5] DrugPatentWatch.com: https://www.drugpatentwatch.com/drug/Secukinumab